Form 4: MannKind CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
MannKind Corp's CEO and Director, Michael Castagna, sold 65,804 shares of common stock at an average price of $6.01 after exercising options.
Summary
- Michael Castagna, Chief Executive Officer and Director of MannKind Corp (MNKD), reported transactions on December 17, 2025.
- Exercised employee stock options to acquire 65,804 shares of common stock, with an exercise price of $4.55 per share.
- Subsequently sold 65,804 shares of common stock at a weighted average price of $6.01 per share, with individual sales prices ranging from $6.00 to $6.04.
- The sale was conducted pursuant to a Rule 10b5-1 plan, which was established on August 8, 2025.
- Following these transactions, Castagna's direct beneficial ownership of MannKind Corp common stock stands at 2,504,792 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While an insider sold shares, it was a planned transaction under a 10b5-1 plan, and the insider profited from exercising options, which can be seen as a positive sign of value realization.
Positives
- The CEO exercised stock options, indicating the options were in-the-money and profitable.
- The sale price of $6.01 per share is higher than the exercise price of $4.55 per share, resulting in a profit for the insider.
- The transaction was executed under a pre-arranged Rule 10b5-1 plan, which suggests a planned liquidity event rather than a reaction to new, non-public information.
Negatives
- The CEO sold a significant number of shares (65,804), reducing his direct beneficial ownership in the company.
Future Outlook
N/A. This filing is a transactional report and does not contain forward-looking statements or guidance.
Industry Context
N/A. This Form 4 filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders may observe a slight reduction in direct insider ownership, though the transaction was pre-planned under a 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 08/02/2018 | Date exercisable for 50,000 employee stock options. |
| 08/07/2023 | Date exercisable for 15,804 employee stock options. |
| 08/08/2025 | Date Rule 10b5-1 Plan was established. |
| 12/17/2025 | Date of stock option exercise and subsequent sale of common stock. |
| 12/19/2025 | Signature date of the reporting person. |
| 05/19/2026 | Expiration date for employee stock options. |
Keywords
MannKind Corp, MNKD, Michael Castagna, CEO, Director, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.